Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California. Show more
400 Seaport Court, Redwood City, CA, 94063, United States
Market Cap
8.706M
52 Wk Range
$1.05 - $9.48
Previous Close
$1.33
Open
$1.36
Volume
9,993
Day Range
$1.28 - $1.42
Enterprise Value
6.059M
Cash
1.717M
Avg Qtr Burn
-887K
Insider Ownership
41.47%
Institutional Own.
2.25%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Burixafor Details Multiple myeloma | Phase 2 Update |